Capital Fund Management S.A. Lowers Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Capital Fund Management S.A. cut its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 50.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 121,433 shares of the company's stock after selling 121,801 shares during the quarter. Capital Fund Management S.A. owned about 0.10% of Apellis Pharmaceuticals worth $3,875,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of APLS. Xponance Inc. lifted its stake in shares of Apellis Pharmaceuticals by 5.6% during the 4th quarter. Xponance Inc. now owns 14,072 shares of the company's stock worth $449,000 after acquiring an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock worth $25,000 after purchasing an additional 758 shares during the last quarter. Signaturefd LLC boosted its stake in shares of Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company's stock valued at $37,000 after purchasing an additional 918 shares during the period. Toronto Dominion Bank grew its holdings in shares of Apellis Pharmaceuticals by 4.2% in the third quarter. Toronto Dominion Bank now owns 25,622 shares of the company's stock worth $739,000 after purchasing an additional 1,022 shares during the last quarter. Finally, US Bancorp DE increased its stake in Apellis Pharmaceuticals by 70.0% in the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after buying an additional 1,327 shares during the period. 96.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, CFO Timothy Eugene Sullivan sold 3,088 shares of the stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $93,967.84. Following the transaction, the chief financial officer now directly owns 129,211 shares of the company's stock, valued at approximately $3,931,890.73. This represents a 2.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel David O. Watson sold 5,569 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares of the company's stock, valued at approximately $3,482,123. The trade was a 3.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,011 shares of company stock worth $1,059,969. 6.80% of the stock is owned by corporate insiders.

Apellis Pharmaceuticals Stock Up 0.2 %

NASDAQ:APLS traded up $0.04 during mid-day trading on Friday, hitting $18.20. 2,455,500 shares of the company's stock traded hands, compared to its average volume of 2,143,821. The company has a fifty day moving average of $23.72 and a 200 day moving average of $28.00. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. Apellis Pharmaceuticals, Inc. has a twelve month low of $17.49 and a twelve month high of $50.98. The company has a market capitalization of $2.28 billion, a P/E ratio of -8.97 and a beta of 0.85.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.08. The business had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company's revenue was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.73) earnings per share. On average, analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

APLS has been the subject of several research reports. Wedbush lowered their price objective on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Scotiabank boosted their price target on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a "sector perform" rating in a report on Wednesday, April 2nd. The Goldman Sachs Group reduced their price objective on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised their price target on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $45.59.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).